Signals via API

Public sample from today's flagship detail endpoint. Public payloads can be limited or redacted. The backend exposes read endpoints for signals, storylines, and briefings.

GET /v1/narratives/203d110e-4449-4c71-b25a-a822f3b5ac81?tenant=biotech&run_id=0e1b4678-65e8-4225-afa4-8a769330e241

{
  "id": "203d110e-4449-4c71-b25a-a822f3b5ac81",
  "title": "Arvinas’ ‘Protac’ breast cancer drug cleared by FDA",
  "summary": "Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.",
  "first_seen_at": "2026-05-01T20:01:00Z",
  "last_seen_at": "2026-05-01T22:38:19Z",
  "created_at": "2026-05-02T05:06:56.717359Z",
  "updated_at": "2026-05-02T17:04:44.796855Z",
  "timeframe": "24h",
  "run_id": "0e1b4678-65e8-4225-afa4-8a769330e241",
  "metrics": {
    "divergence": 8.6603,
    "post_count": 3,
    "momentum_1h": 0,
    "momentum_7d": 3,
    "score_total": 1.523199,
    "shill_score": 10,
    "momentum_24h": 3,
    "market_movers": [],
    "evidence_score": 0.75,
    "unique_authors": 3,
    "coherence_score": 0.8012,
    "diversity_bonus": 0.2125,
    "duplicate_ratio": 0,
    "platforms_count": 2,
    "social_momentum": 3,
    "divergence_label": "chatter_without_pricing",
    "market_conviction": 0,
    "origin_share_top1": 0.333333,
    "unique_publishers": 3,
    "origin_layer_posts": 0,
    "source_types_count": 2,
    "unique_authors_24h": 3,
    "unique_origin_urls": 3,
    "amplifier_share_top1": 0.333333,
    "author_concentration": 0.3333,
    "publisher_share_top1": 0.333333,
    "amplifier_layer_posts": 3,
    "concentration_penalty": 0,
    "unique_origin_domains": 3,
    "source_diversity_bonus": 0.2,
    "unique_publisher_types": 2,
    "unique_origin_publishers": 3
  },
  "platforms": [
    "reddit",
    "rss"
  ],
  "top_tickers": [],
  "why_now": [],
  "display_title": "FDA approves Pfizer and Arvinas' novel breast cancer drug Veppanu",
  "display_summary": "The US FDA has granted early approval to Veppanu (vepdegestrant), a novel breast cancer drug developed by Arvinas and Pfizer. Veppanu is the first drug of its kind to reach the market, offering a new treatment option for certain breast cancer patients.",
  "narrative_frame_display": "Veppanu, developed by Arvinas and Pfizer, received early FDA approval as a first-in-class breast cancer treatment. This milestone expands therapeutic options for patients with certain breast cancers. However, Pfizer and Arvinas plan to partner with another company for commercialization, indicating ongoing strategic efforts post-approval.",
  "entities": {
    "projects": [
      "Veppanu"
    ],
    "companies": [
      "Pfizer",
      "Arvinas"
    ]
  },
  "recurring_claims": [
    {
      "claim": "The FDA granted early approval to Veppanu, a novel breast cancer drug developed by Pfizer and Arvinas.",
      "evidence_urls": [
        "https://reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizer-arvinas-breast-cancer-drug-2026-05-01",
        "https://biopharmadive.com/news/arvinas-pfizer-fda-approve-veppanu-vepdegestrant-breast-cancer/819108",
        "https://fiercepharma.com/pharma/fda-hands-pfizer-arvinas-veppanu-early-approval-certain-breast-cancer"
      ]
    },
    {
      "claim": "Pfizer and Arvinas are seeking a commercialization partner to market Veppanu despite FDA approval.",
      "evidence_urls": [
        "https://biopharmadive.com/news/arvinas-pfizer-fda-approve-veppanu-vepdegestrant-breast-cancer/819108",
        "https://fiercepharma.com/pharma/fda-hands-pfizer-arvinas-veppanu-early-approval-certain-breast-cancer"
      ]
    }
  ],
  "stance_map": [
    {
      "stance": "neutral",
      "who": "news reports",
      "evidence_urls": [
        "https://reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizer-arvinas-breast-cancer-drug-2026-05-01",
        "https://biopharmadive.com/news/arvinas-pfizer-fda-approve-veppanu-vepdegestrant-breast-cancer/819108"
      ]
    }
  ],
  "quality_flags": {
    "mixed_topic_risk": "low",
    "promo_risk": "low",
    "source_quality": "high"
  },
  "editor_note": "Consolidated multiple sources to provide a clear summary of Veppanu's FDA approval and commercialization plans.",
  "display_tags": [
    "clinical_trials",
    "fda",
    "approvals",
    "drug_development"
  ],
  "tags": [
    "clinical_trials",
    "fda",
    "approvals",
    "drug_development"
  ],
  "cscope_tags": [
    "clinical_trials",
    "fda",
    "approvals",
    "drug_development"
  ],
  "why_now_display": [
    "The approval was granted recently, marking a significant regulatory event.",
    "Pfizer and Arvinas are actively seeking commercialization partners now that the drug is approved.",
    "Early approval may accelerate patient access to this novel therapy."
  ],
  "why_it_matters_display": [
    "Veppanu is the first drug of its kind approved for breast cancer, expanding treatment options.",
    "FDA approval is a key regulatory milestone enabling further development and patient access.",
    "The search for a commercialization partner highlights strategic considerations post-approval."
  ],
  "show_why": true,
  "sources_display": [
    {
      "label": "reuters.com: US FDA approves Pfizer, Arvinas breast cancer drug (via Reddit)"
    },
    {
      "label": "biopharmadive.com: Arvinas’ ‘Protac’ breast cancer drug cleared by FDA"
    },
    {
      "label": "fiercepharma.com: FDA hands Pfizer, Arvinas Veppanu early approval for certain breast cancer"
    }
  ],
  "trend_status": "flat",
  "trend_sparkline": "▁▁",
  "trend_points_n": 0,
  "trend_window": {
    "lookback_days": 14,
    "max_points": 36,
    "value_key": null
  },
  "llm_status": "accepted",
  "llm_meta": {
    "model": "gpt-4.1-mini-2025-04-14",
    "prompt_version": "enrich_v3",
    "input_hash": "844dac5ff9223ad17df556621fc23247314efe6ad594d2907c81eb2eafb36534",
    "updated_at": "2026-05-02T17:07:36.019234+00:00",
    "llm_metadata": {
      "env": "prod",
      "host": "1ac770f65f4e",
      "stage": "signals.enrich",
      "run_id": "0e1b4678-65e8-4225-afa4-8a769330e241",
      "tenant": "biotech",
      "service": "api",
      "pipeline": "pipeline_run",
      "correlation_id": "203d110e-4449-4c71-b25a-a822f3b5ac81"
    }
  },
  "story_id": "109e7e6a-45cf-43cc-a809-a1a32245a239",
  "public_surface": {
    "eligible_for_flagship_sample": true,
    "eligible_for_top_public_brief": true,
    "eligible_for_public_index": true,
    "eligible_only_for_lower_or_internal_surfaces": false,
    "public_rank_score": 13,
    "structural_priority": true,
    "mostly_social": false,
    "community_chatter": false,
    "reader_label": null,
    "excluded_reasons": [],
    "source_signals": {
      "post_count": 3,
      "unique_origins": 3,
      "source_types_count": 2,
      "independent_non_social_count": 3,
      "social_source_count": 0,
      "non_social_source_count": 0,
      "why_now_count": 3,
      "why_it_matters_count": 3
    }
  },
  "current_cycle_open": false
}

• Signals and storylines feed endpoints with filtering and rate limits
• Briefing delivery endpoints for integrations
• Evidence link payloads for auditability

• Route top stories into Slack or Teams for morning and evening desk updates.
• Sync storyline evidence into Notion, Airtable, or internal research trackers.
• Feed metrics into BI dashboards for momentum, concentration, and source mix monitoring.

Quick start endpoints: /v1/feed/stories, /v1/signals, /v1/storylines/search, /v1/briefings/latest.

For product access, see Pricing.